Semaglutide Breaks the 'Diabetes Barrier' for Cardiovascular Protection

SELECT Trial: 20% reduction in MACE among non-diabetic patients with obesity and CVD, driven by mechanisms beyond simple weight loss

Design SELECT Trial Population Age ≥45, BMI ≥27, Established CVD, No Diabetes N 17,604 Duration Mean follow-up 39.8 months Comparator Placebo vs. Semaglutide 2.4 mg Year 2023

Key Performance Indicators

PRIMARY

Primary Endpoint (MACE) HR

0.80

95% CI: 0.72–0.90; P<0.001

20% Relative Risk Reduction

Absolute Risk Reduction

1.5%

NNT ≈ 67 over ~40 months

8.0% (Placebo) vs 6.5% (Sema)

CRP Reduction

-39%

vs -2% in Placebo

Strong anti-inflammatory effect

Weight Loss

9.4%

Mean reduction at 104 weeks

vs 0.9% in Placebo

01

Early and Sustained Divergence in Cardiovascular Risk

Cumulative incidence of the primary composite endpoint (CV death, nonfatal MI, nonfatal stroke) shows separation appearing shortly after initiation.

02

Consistent Benefit Across Major Cardiac Events

Hazard ratios favor Semaglutide across the primary composite and key secondary endpoints, though stroke reduction did not reach significance.

03

Deep Impact on Inflammatory and Metabolic Drivers

Percentage change from baseline to week 104 reveals massive reductions in CRP and Triglycerides, suggesting mechanisms beyond simple weight loss.

04

Safety Trade-off: GI Tolerability vs. Serious Event Reduction

While Semaglutide caused higher discontinuation due to GI issues, it actually reduced the overall rate of Serious Adverse Events compared to placebo.

05

Reversing Metabolic Dysfunction

Among patients with prediabetes at baseline, Semaglutide treatment led to normoglycemia in 66% of cases by week 52, compared to only 20% with placebo.

Editorial Conclusion

“Semaglutide demonstrates a 20% reduction in major cardiovascular events in non-diabetic patients, establishing obesity treatment as a direct pillar of cardiovascular prevention.”

Benefit is driven by a combination of weight loss (-9.4%) and potent anti-inflammatory effects (CRP -39%).

Despite higher GI-related discontinuations (10%), the overall serious adverse event rate was lower in the treatment arm (33.4% vs 36.4%).

Results support expanding GLP-1 usage to secondary prevention in obesity, regardless of glycemic status.

Clinical Implication

This trial effectively reclassifies obesity from a comorbidity to a primary modifiable risk factor for CVD, warranting aggressive pharmacotherapy.

Reference Data & Sources

Complete Data Table

viz_id	chart_type	label	group	value	low	high	p	sig	unit	category	x	y
viz1	line_chart	Baseline	Placebo
viz1	line_chart	Year 1	Placebo								12	2.1
viz1	line_chart	Year 2	Placebo								24	4.2
viz1	line_chart	Year 3	Placebo								36	6.1
viz1	line_chart	Year 4	Placebo								48	8.0
viz1	line_chart	Baseline	Semaglutide
viz1	line_chart	Year 1	Semaglutide								12	1.6
viz1	line_chart	Year 2	Semaglutide								24	3.4
viz1	line_chart	Year 3	Semaglutide								36	4.9
viz1	line_chart	Year 4	Semaglutide								48	6.5
viz2	forest	Primary Composite (MACE)	Composite	0.8	0.72	0.9	<0.001	True
viz2	forest	CV Death	Component	0.85	0.71	1.01	0.07
viz2	forest	Nonfatal MI	Component	0.72	0.61	0.85		True
viz2	forest	Nonfatal Stroke	Component	0.93	0.74	1.15
viz2	forest	Heart Failure Composite	Secondary	0.82	0.71	0.96		True
viz2	forest	All-Cause Death	Secondary	0.81	0.71	0.93		True
viz3	diverging_bar	High-sensitivity CRP	Semaglutide	-39.12						Inflammation
viz3	diverging_bar	High-sensitivity CRP	Placebo	-2.08						Inflammation
viz3	diverging_bar	Triglycerides	Semaglutide	-18.34						Lipids
viz3	diverging_bar	Triglycerides	Placebo	-3.2						Lipids
viz3	diverging_bar	Body Weight	Semaglutide	-9.39						Anthropometric
viz3	diverging_bar	Body Weight	Placebo	-0.88						Anthropometric
viz3	diverging_bar	Waist Circumference	Semaglutide	-7.56						Anthropometric
viz3	diverging_bar	Waist Circumference	Placebo	-1.03						Anthropometric
viz3	diverging_bar	LDL Cholesterol	Semaglutide	-5.25						Lipids
viz3	diverging_bar	LDL Cholesterol	Placebo	-3.14						Lipids
viz4	dumbbell	Serious Adverse Events (Total)	Semaglutide	33.4					%
viz4	dumbbell	Serious Adverse Events (Total)	Placebo	36.4					%
viz4	dumbbell	Discontinuation (Any AE)	Semaglutide	16.6					%
viz4	dumbbell	Discontinuation (Any AE)	Placebo	8.2					%
viz4	dumbbell	Discontinuation (GI Disorders)	Semaglutide	10.0					%
viz4	dumbbell	Discontinuation (GI Disorders)	Placebo	2.0					%
viz4	dumbbell	Gallbladder-related Disorders	Semaglutide	2.8					%
viz4	dumbbell	Gallbladder-related Disorders	Placebo	2.3					%
viz5	slope_chart	Semaglutide	Semaglutide								Baseline (Prediabetes)	100
viz5	slope_chart	Semaglutide	Semaglutide								Week 52 (Normoglycemia)	66.0
viz5	slope_chart	Placebo	Placebo								Baseline (Prediabetes)	100
viz5	slope_chart	Placebo	Placebo								Week 52 (Normoglycemia)	19.8

Abbreviations

Abbrev	Meaning
MACE	Major Adverse Cardiovascular Events
HR	Hazard Ratio
CI	Confidence Interval
CRP	C-Reactive Protein
GI	Gastrointestinal

Source

N Engl J Med 2023;389:2221-32

DOI: 10.1056/NEJMoa2307563

Limitations

Trial included only secondary prevention (established CVD).
Low representation of Black patients (3.8%) and women (27.7%).
High discontinuation rate due to adverse events in the treatment arm.